Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.61 |
| ▸ | MAPT | P10636 | 5/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | ILK | Q13418 | 1/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1968361 | 0.81 | ALDH1A1 (0.47) | ALDH1A1MAPTKDM4ECYP2C9CYP2C19 | |
| SCHEMBL1968562 | 0.76 | MAPK1 (0.52) | ALDH1A1MAPTLMNASMN1; SMN2MEN1 | |
| SCHEMBL16311044 | 0.76 | KMT2A (0.58) | ALDH1A1MAPTKDM4ECYP2C9CYP2C19 | |
| SCHEMBL4956705 | 0.75 | POLB (0.53) | ALDH1A1MAPTKDM4ECYP2C9CYP2C19 | |
| SCHEMBL22658875 | 0.75 | ALDH1A1 (0.45) | ALDH1A1MAPTKDM4ECYP2C9CYP2C19 | |
| SCHEMBL4960060 | 0.74 | CTSA (0.47) | ALDH1A1MAPTKDM4ECYP2C9CYP2C19 | |
| SCHEMBL4961091 | 0.74 | TRPM8 (0.46) | ALDH1A1MAPTKDM4ECYP2C9CYP2C19 | |
| SCHEMBL4956714 | 0.73 | HPGD (0.53) | ALDH1A1MAPTKDM4ELMNASMN1; SMN2 | |
| SCHEMBL4959888 | 0.72 | ALDH1A1 (0.56) | ALDH1A1MAPTLMNASMN1; SMN2HPGD | |
| SCHEMBL13224737 | 0.72 | SMN1; SMN2 (0.56) | ALDH1A1MAPTKDM4ECYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312291-A1 | Heterocyclic Gaba-b Modulators | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | claimed |
| EP-1966176-A1 | HETEROCYCLIC GABA-B MODULATORS | AstraZeneca AB (SE) | 2008-09-10 | — | — | EP | claimed |
| WO-2007073296-A1 | HETEROCYCLIC GABA-B MODULATORS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | claimed |
| US-20080312291-A1 | Heterocyclic Gaba-b Modulators | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080312291-A1 | Heterocyclic Gaba-b Modulators | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080312291-A1 | Heterocyclic Gaba-b Modulators | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| EP-1966176-A1 | HETEROCYCLIC GABA-B MODULATORS | AstraZeneca AB (SE) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007073296-A1 | HETEROCYCLIC GABA-B MODULATORS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312291-A1 | Heterocyclic Gaba-b Modulators | GABBR1, GABBR2, GABRB1 | ALDH1A1 1429/4885MAPT 3842/4885KDM4E 3425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.